anti-cd20 b9e9 scfv-streptavidin fusion protein
mAbexperimentalImaging agent
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2017 (NCT02483000)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD20INHIBITOR
MS4A1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- anti-cd20 b9e9 scfv-streptavidin fusion protein
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02483000 | Phase 1 | Feb 1, 2017 | National Cancer Institute (NCI), University of Washington |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2017 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1